Atezolizumab Plus Bevacizumab Combination Therapy Compared to Sorafenib and Atezolizumab Monotherapies for Treatment of Unresectable or Metastatic Hepatocellular Carcinoma

Background/Aim

  • Sorafenib has been the historical first-line treatment of choice for unresectable or metastatic hepatocellular carcinoma (HCC) since 2007. 


  • However, on May 29, 2020, FDA approved atezolizumab plus bevacizumab (AB) combination for HCC and gave it priority over sorafenib. 


  • Here, we performed a systematic review evaluating the efficacy and safety of combination immunogenic chemotherapy as first-line therapy as opposed to sorafenib (S) and atezolizumab (A) monotherapies.
Overall Rating

0

5 Star
(0)
4 Star
(0)
3 Star
(0)
2 Star
(0)
1 Star
(0)
APA

GUDAPATI, S. (2021). Atezolizumab Plus Bevacizumab Combination Therapy Compared to Sorafenib and Atezolizumab Monotherapies for Treatment of Unresectable or Metastatic Hepatocellular Carcinoma. Afribary. Retrieved from https://track.afribary.com/works/apdworale-posterpresentationbyprathima

MLA 8th

GUDAPATI, SRAVYA "Atezolizumab Plus Bevacizumab Combination Therapy Compared to Sorafenib and Atezolizumab Monotherapies for Treatment of Unresectable or Metastatic Hepatocellular Carcinoma" Afribary. Afribary, 25 Aug. 2021, https://track.afribary.com/works/apdworale-posterpresentationbyprathima. Accessed 23 Nov. 2024.

MLA7

GUDAPATI, SRAVYA . "Atezolizumab Plus Bevacizumab Combination Therapy Compared to Sorafenib and Atezolizumab Monotherapies for Treatment of Unresectable or Metastatic Hepatocellular Carcinoma". Afribary, Afribary, 25 Aug. 2021. Web. 23 Nov. 2024. < https://track.afribary.com/works/apdworale-posterpresentationbyprathima >.

Chicago

GUDAPATI, SRAVYA . "Atezolizumab Plus Bevacizumab Combination Therapy Compared to Sorafenib and Atezolizumab Monotherapies for Treatment of Unresectable or Metastatic Hepatocellular Carcinoma" Afribary (2021). Accessed November 23, 2024. https://track.afribary.com/works/apdworale-posterpresentationbyprathima